In summary, we believe that the correlation between treatment response to immune-checkpoint inhibitors and the occurrence of irAEs and HLA signature in cancer patients deserves further investigation in large perspective studies.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: